logo-loader
Botanix Pharmaceuticals Ltd

Botanix Pharmaceuticals raises $40mln to push its CBD-based skin disease treatments through the pipeline

Botanix Pharmaceuticals Limited (ASX:BOT) CEO Matt Callahan tells Proactive Investors the clinical-stage pharma company has raised $40 million.

Callahan says the cash will allow the Sydney, Australia, and Philadelphia, Pennsylvania-based company to accelerate its preclinical and clinical work in bringing its CBD-based skin disease treatments to phase 3. Additionally, these funds will allow the company to bring into the clinic its first application of CBD as a stand-alone antimicrobial. 

Quick facts: Botanix Pharmaceuticals Ltd

Price: $0.21

Market: ASX
Market Cap: $197.72 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

'May only be a matter of time' before Uranium price recovery with...

Mining Capital's Alastair Ford discusses the planned slow down in production from Kazatomprom (LON:KAP). The miner's looking to cut output from its Kazakh mines by around 20% through to 2021. He says that extends the timeframe of its previous production curtailment by a further year, and...

12 hours, 55 minutes ago

2 min read